China Pharma Holdings (CPHI) Receivables - Net (2010 - 2026)

China Pharma Holdings (CPHI) has reported Receivables - Net for 17 consecutive years, with $195849.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net fell 98.59% year-over-year to $195849.0; the trailing twelve-month figure through Jun 2026 stood at $195849.0 (down 98.59% YoY), and the FY2025 full-year result was $254435.0, down 98.16% from the prior year.
• Receivables - Net slipped to $195849.0 in Q2 2026 per CPHI's latest filing, from $205696.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $14.3 million in Q4 2023 and bottomed at $39019.0 in Q1 2022.
• Historically, Receivables - Net has averaged $5.6 million across 5 years, with a median of $331370.5 in 2023.
• The sharpest annual moves came in 2024 and 2026: Receivables - Net surged 13063.85% in 2024, then plunged 98.59% in 2026.
• Over 5 years, Receivables - Net stood at $421531.0 in 2022, then jumped by 3290.15% to $14.3 million in 2023, then decreased by 3.3% to $13.8 million in 2024, then slumped by 98.16% to $254435.0 in 2025, then dropped by 23.03% to $195849.0 in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $195849.0, $205696.0, and $254435.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.